OpsMind is a Watch, not a lead: we should engage but withhold a term sheet until two data gaps close. The strongest reason for is genuine, quantified pain relief—median triage cut from 22 to 6 minutes across 40 teams—in a large, growing AIOps market where the switching-cost moat, if earned, is durable. The strongest reason against is that OpsMind's differentiation is a feature incumbents already own: Datadog, PagerDuty (its own integration partner), and Splunk are bundling LLM root-cause copilots for free, so willingness-to-pay may erode just as seat-based pricing collapses under AI-reduced headcount. Compounding this, the MRR figure is internally contradictory ($34k vs $408k), and no RCA accuracy, LTV/CAC, inference-COGS, or NRR data was disclosed. Plan: offer to co-invest up to $2M for ~9.9% at a ~$16M pre, staged—release a first tranche only against verified top-1 RCA accuracy, cohort retention/NRR, and per-incident inference margins. Reserve $3M for pro-rata. Pass if pricing stays seat-based.
Stress test needs unit economics — disclose LTV/CAC (or CAC and LTV) to model CAC, churn and margin shocks.
Market-size and growth figures for B2B SaaS (horizontal) are anchored to recent third-party research: